Mucinoses Clinical Trial
Official title:
A Clinical Study of Tranilast in the Treatment of Mucinoses
Verified date | February 2018 |
Source | The First Affiliated Hospital with Nanjing Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
56 participants with Mucinoses will be selected to receive treatment of tranilast. After a period of time ,the investigators can determine the efficacy of the drug by detecting the the thickness and area of skin before and after treatment.
Status | Not yet recruiting |
Enrollment | 56 |
Est. completion date | December 2022 |
Est. primary completion date | June 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Clinical and histopathological examination has been proved to be Mucinoses; 2. Ultrasound and magnetic resonance detection found that the skin was thickened. Exclusion Criteria: 1. With a liver or kidney disease, or accompanied by a severe infection; 2. Poor control of primary disease; 3. With mental disease. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital with Nanjing Medical University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measure the volume change of skin lesions by ultrasound | During tranilast (0.1g each time, three times a day, 12 months) treatment, patients need to test lesion volume.The reduction of volume greater than 50% is judged to be effective | This experiment will last for 12 months |